Combining GLP ‐1 Receptor Agonists and Health‐Behaviour and Lifestyle Therapy Yields Higher Adherence and Reduces Session Needs for Successful Weight Management in Adolescence: An Observational Real‐World Single‐Center Study
Pediatric Obesity · 2026-06 · 21 (6)
DOI: 10.1111/ijpo.70122 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Pediatric Obesity, online erschienen am 01.06.2026. Verfasst von Julia Lischka und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Paracelsus Medical University, Salzburg, Austria. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Health Behavior, Liraglutide, Patient Compliance. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Evidence for the role of health behaviour and lifestyle treatment (HBLT) on the effectiveness of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) in paediatric obesity is limited.
Objectives
To assess the role of HBLT on the effectiveness of GLP‐1RAs in youth with obesity.
Methods
Patients aged 8–18 years with obesity ( n = 51) receiving liraglutide were retrospectively divided into continuers (ongoing liraglutide treatment), discontinuers, or switches to semaglutide or metabolic‐bariatric surgery. All were offered multidisciplinary HBLT and consecutively allocated to either high‐frequency (HF) HBLT (≥ 26 contact hours/year) or low‐frequency obesity medication (OM)‐specific HBLT (9 contacts of 0.5 h/year).
Results
After 9.7 ± 6.6 months, a BMI reduction of ≥ 5% and ≥ 10% was observed in 37.3% and 13.7%, respectively. Relative change in BMI was higher in continuers compared to discontinuers (−6.7% ± 7.5% vs. −0.7% ± 5.1%, p = 0.03). Whereas 39.2% of patients continued liraglutide, 33.3% discontinued, mainly due to gastrointestinal symptoms. 27.4% of patients switched treatment to semaglutide or underwent surgery. Patients with combined HBLT and liraglutide had markedly higher odds of continuation (OR 18.5, 95% CI 2.0–929.8, p < 0.01) and greater reductions in BMI, which was by trend higher with OM‐HBLT compared to HF‐HBLT (BMI change −6.9% ± 7.2% vs. −4.0% ± 6.6%).
Conclusions
GLP‐1RAs were effective in the real‐world treatment of paediatric obesity. HBLT appears to be essential to increase persistence and efficacy of GLP‐1RAs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Paracelsus Medical University, Salzburg, Austria.
- Obesity Research Unit, Paracelsus Medical University, Salzburg, Austria.
- Department of Pediatrics, Paracelsus Medical University, Klinikum Nürnberg, Universitätsklinik der Paracelsus Medizinischen Privatuniversität Nürnberg, Nuremberg, Germany.
- Department of Family Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
- Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
- Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden.
ORCID-Profile: Julia Lischka, Gabriel Torbahn, Michael Vallis, Daniel Weghuber
Zitieren
APA
Lischka, J., Torbahn, G., Vallis, M., Mörwald, K., Gomahr, J., Forslund, A., Stenlid, R., Manell, H., Bergsten, P., Geiersberger, S., Bergauer, M., Forer, L., Lauth, W., Jabbour, J., Döttl, L., Swittalek, M., Lanzinger, S., & Weghuber, D. (2026). Combining GLP ‐1 Receptor Agonists and Health‐Behaviour and Lifestyle Therapy Yields Higher Adherence and Reduces Session Needs for Successful Weight Management in Adolescence: An Observational Real‐World Single‐Center Study. Pediatric Obesity, 21(6). https://doi.org/10.1111/ijpo.70122
Vancouver
Lischka J, Torbahn G, Vallis M, Mörwald K, Gomahr J, Forslund A, et al. Combining GLP ‐1 Receptor Agonists and Health‐Behaviour and Lifestyle Therapy Yields Higher Adherence and Reduces Session Needs for Successful Weight Management in Adolescence: An Observational Real‐World Single‐Center Study. Pediatric Obesity. 2026;21(6). doi:10.1111/ijpo.70122
BibTeX
@article{Lischka2026,
author = {Lischka, Julia and Torbahn, Gabriel and Vallis, Michael and Mörwald, Katharina and Gomahr, Julian and Forslund, Anders and Stenlid, Rasmus and Manell, Hannes and Bergsten, Peter and Geiersberger, Sabine and Bergauer, Max and Forer, Lotte and Lauth, Wanda and Jabbour, Jeanne and Döttl, Laura and Swittalek, Maria and Lanzinger, Stefanie and Weghuber, Daniel},
title = {Combining GLP ‐1 Receptor Agonists and Health‐Behaviour and Lifestyle Therapy Yields Higher Adherence and Reduces Session Needs for Successful Weight Management in Adolescence: An Observational Real‐World Single‐Center Study},
journal = {Pediatric Obesity},
year = {2026},
volume = {21},
number = {6},
doi = {10.1111/ijpo.70122}
}
EUVIMED